Marginal zone lymphoma (MZL) is a condition wherein B cells in lymphoid tissue are affected by a rare class of slow-growing non-Hodgkin lymphoma. The second most frequent indolent non-Hodgkin's lymphoma, it accounts for around 8% of non-Hodgkin lymphoma patients. Marginal zone lymphoma can be categorized into three types, namely, extranodal, splenic, and nodal. Splenic MZL (SMZL) is limited to the spleen, bone marrow, and blood, whereas extranodal MZL (EMZL) can transpire in tissues devoid of lymphoid tissue. Only lymph nodes are affected by nodal MZL (NMZL), which is the least prevalent type. The affected tissues, clinical presentation, and management of the three types vary. Moreover, its rising prevalence is anticipated to positively impact the pipeline landscape for marginal zone lymphoma drugs.
Report Coverage
The Marginal Zone Lymphoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into marginal zone lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for marginal zone lymphoma. The marginal zone lymphoma report assessment includes the analysis of over 25 pipeline drugs and 10+ companies. The marginal zone lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with marginal zone lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to marginal zone lymphoma.
Marginal Zone Lymphoma Drug Pipeline Outlook
The pathophysiology of marginal zone lymphoma includes long-term B-cell stimulation from infection or autoimmune, which results in genetic abnormalities and B-cell receptor stimulation. Dysregulation of BCR signaling can activate the NF-κB pathway, which is essential for marginal zone lymphoma growth. Immune cross-reactions brought on by prolonged exposure to stimuli are frequently linked to extranodal marginal zone lymphoma. Chromosome translocations, proto-oncogene mutations, and changes in MALT1 and BCL10 levels are examples of genetic abnormalities that are essential for lymphomagenesis. The pathophysiology of splenic marginal zone lymphoma most likely include ongoing BCR signaling activation.
Anti-CD20 monoclonal antibodies, especially rituximab, are frequently preferred for treating marginal zone lymphoma, either in combination with chemotherapy or on its own. Because rituximab is an indolent drug, it is recommended for asymptomatic individuals to get it as a single drug. For symptomatic, advanced-stage marginal zone lymphoma, chemoimmunotherapy, such as bendamustine-rituximab (BR), is the primary line of treatment. The objective response rate among patients using the anti-CD20 monoclonal antibody therapy has shown to be around 81%. When compared to other regimens such as R with Chlorambucil and R-CVP, BR exhibits higher efficacy and safety. Further, the rising focus on the development of marginal zone lymphoma emerging drugs and the advances in the understanding of the molecular pathogenesis of the disease are expected to support the pipeline expansion in the coming years.
Marginal Zone Lymphoma Epidemiology
Making up around 7% of all occurrences, marginal zone lymphoma is a minor subset of non-Hodgkin lymphomas (NHL). Approximately 7,460 new diagnoses were made in the United States in 2016. The incidence of marginal zone lymphoma was 19.6 per 1,000,000 person-years, age-standardized. After nodal and splenic marginal zone lymphoma, extranodal marginal zone lymphoma is the most prevalent subtype. Men are slightly more likely to have splenic and nodal marginal zone lymphoma, and incidence rates rise with age. marginal zone lymphoma has a 5-year relative survival rate of about 89.8% in the United States.
Marginal Zone Lymphoma – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of marginal zone lymphoma drug candidates based on several segmentations including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Monoclonal Antibodies
- Small Molecule Inhibitors
- Immunomodulators
- Others
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials, with a substantial number of marginal zone lymphoma drugs undergoing clinical development.
Marginal Zone Lymphoma – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under marginal zone lymphoma pipeline analysis include small molecules, biologics, peptides, and immunotherapies, among others. The marginal zone lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for marginal zone lymphoma.
Marginal Zone Lymphoma Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the marginal zone lymphoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed marginal zone lymphoma assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in marginal zone lymphoma clinical trials:
- Novartis Pharmaceuticals
- Eli Lilly and Company
- Incyte Corporation
- Loxo Oncology, Inc.
- Biegene
- Adicet Therapeutics
- Genmab
- ArQule, Inc.
- Cellectar Biosciences, Inc.
- Acerta Pharma BV
- Prelude Therapeutics
Major drugs currently in the drug pipeline are as follows:
Drug: VAY736
VAY736, also called Ianalumab, is a monoclonal antibody that targets the BAFF receptor. It is being developed by Novartis Pharmaceuticals and is currently under Phase I clinical development. It is under investigation as a possible treatment option for marginal zone lymphoma because it inhibits B-cell survival and proliferation by blocking the BAFF signaling pathway. VAY736 may be used to target the aberrant B-cells that contribute to the development of marginal zone lymphoma.
Drug: LOXO-305
Eli Lilly and Company is sponsoring a clinical trial for LOXO-305, sometimes referred to as pirtobrutinib. It is a highly selective, next-generation inhibitor of Bruton's tyrosine kinase (BTK), intended to decrease BTK activity and overcome resistance shown with previous BTK inhibitors to target B-cell malignancies, particularly marginal zone lymphoma. Clinical trials are now being conducted to assess the safety and effectiveness of pirtobrutinib in the treatment of relapsed or refractory MZL and other B-cell malignancies. The study is under Phase I clinical development.
Reasons To Buy This Report
The Marginal Zone Lymphoma Drug Report provides a strategic overview of the latest and future landscape of treatments for marginal zone lymphoma. it provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within marginal zone lymphoma pipeline insights.
Key Questions Answered in the Marginal Zone Lymphoma – Pipeline Insight Report
- What is the current landscape of marginal zone lymphoma pipeline drugs?
- Which companies/institutions are developing marginal zone lymphoma emerging drugs?
- How many phase II drugs are currently present in marginal zone lymphoma pipeline drugs?
- Which company is leading the marginal zone lymphoma pipeline development activities?
- What is the current marginal zone lymphoma therapeutic assessment?
- What are the opportunities and challenges present in the Marginal Zone Lymphoma drug pipeline landscape?
- What is the efficacy and safety profile of marginal zone lymphoma pipeline drugs?
- Which companies/institutions are involved in marginal zone lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Marginal Zone Lymphoma?
Global Cancer Therapeutics Market
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Marginal Zone Lymphoma
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Types of Marginal Zone Lymphoma
- 3.5 Diagnosis
- 3.6 Treatment
- 4 Patient Profile: Marginal Zone Lymphoma
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Marginal Zone Lymphoma: Epidemiology Snapshot
- 5.1 Marginal Zone Lymphoma Incidence by Key Markets
- 5.2 Marginal Zone Lymphoma – Patients Seeking Treatment in Key Markets
- 6 Marginal Zone Lymphoma: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Marginal Zone Lymphoma: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Marginal Zone Lymphoma, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Marginal Zone Lymphoma Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Marginal Zone Lymphoma Drug Pipeline - Mid-Stage Products (Phase III & IV) (Top Drugs)
- 10.1 Comparative Analysis for Mid-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: Tafasitamab
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Marginal Zone Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: LOXO-305
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Zanubrutinib
- 11.2.3 Other Drugs
- 12 Marginal Zone Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug: VAY736
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Drug: ADI-001
- 12.2.3 Other Drugs
- 13 Marginal Zone Lymphoma, Key Drug Pipeline Companies
- 13.1 Novartis Pharmaceuticals
- 13.1.1 Company Snapshot
- 13.1.2 Pipeline Product Portfolio
- 13.1.3 Financial Analysis
- 13.1.4 Recent News and Developments
- 13.2 Eli Lilly and Company
- 13.2.1 Company Snapshot
- 13.2.2 Pipeline Product Portfolio
- 13.2.3 Financial Analysis
- 13.2.4 Recent News and Developments
- 13.3 Incyte Corporation
- 13.3.1 Company Snapshot
- 13.3.2 Pipeline Product Portfolio
- 13.3.3 Financial Analysis
- 13.3.4 Recent News and Developments
- 13.4 Loxo Oncology, Inc.
- 13.4.1 Company Snapshot
- 13.4.2 Pipeline Product Portfolio
- 13.4.3 Financial Analysis
- 13.4.4 Recent News and Developments
- 13.5 BeiGene
- 13.5.1 Company Snapshot
- 13.5.2 Pipeline Product Portfolio
- 13.5.3 Financial Analysis
- 13.5.4 Recent News and Developments
- 13.6 Adicet Therapeutics
- 13.6.1 Company Snapshot
- 13.6.2 Pipeline Product Portfolio
- 13.6.3 Financial Analysis
- 13.6.4 Recent News and Developments
- 13.7 Genmab
- 13.7.1 Company Snapshot
- 13.7.2 Pipeline Product Portfolio
- 13.7.3 Financial Analysis
- 13.7.4 Recent News and Developments
- 13.8 ArQule, Inc.
- 13.8.1 Company Snapshot
- 13.8.2 Pipeline Product Portfolio
- 13.8.3 Financial Analysis
- 13.8.4 Recent News and Developments
- 13.9 Cellectar Biosciences, Inc.
- 13.9.1 Company Snapshot
- 13.9.2 Pipeline Product Portfolio
- 13.9.3 Financial Analysis
- 13.9.4 Recent News and Developments
- 13.10 Acerta Pharma BV
- 13.10.1 Company Snapshot
- 13.10.2 Pipeline Product Portfolio
- 13.10.3 Financial Analysis
- 13.10.4 Recent News and Developments
- 13.11 Prelude Therapeutics
- 13.11.1 Company Snapshot
- 13.11.2 Pipeline Product Portfolio
- 13.11.3 Financial Analysis
- 13.11.4 Recent News and Developments
- 14 Regulatory Framework for Drug Approval, By Region
- 15 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook